Cargando…
Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
BACKGROUND: Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772091/ https://www.ncbi.nlm.nih.gov/pubmed/24069296 http://dx.doi.org/10.1371/journal.pone.0074345 |
_version_ | 1782284282022068224 |
---|---|
author | Cuppini, Lucia Calleri, Angelica Bruzzone, Maria Grazia Prodi, Elena Anghileri, Elena Pellegatta, Serena Mancuso, Patrizia Porrati, Paola Di Stefano, Anna Luisa Ceroni, Mauro Bertolini, Francesco Finocchiaro, Gaetano Eoli, Marica |
author_facet | Cuppini, Lucia Calleri, Angelica Bruzzone, Maria Grazia Prodi, Elena Anghileri, Elena Pellegatta, Serena Mancuso, Patrizia Porrati, Paola Di Stefano, Anna Luisa Ceroni, Mauro Bertolini, Francesco Finocchiaro, Gaetano Eoli, Marica |
author_sort | Cuppini, Lucia |
collection | PubMed |
description | BACKGROUND: Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated in 68 patients affected by recurrent glioblastoma (rGBM) treated with bevacizumab and irinotecan and two Independent Datasets of rGBM patients respectively treated with bevacizumab alone (n=32, independent dataset A: IDA) and classical antiblastic chemotherapy (n=14, independent dataset B: IDB). METHODS: rGBM patients with KPS ≥50 were treated until progression, as defined by MRI with RANO criteria. CECs expressing CD109, a marker of tumor endothelial cells, as well as other CEC and CEP subtypes, were investigated by six-color flow cytometry. RESULTS: A baseline count of CD109+ CEC higher than 41.1/ml (1(st) quartile) was associated with increased progression free survival (PFS; 20 versus 9 weeks, P=0.008) and overall survival (OS; 32 versus 23 weeks, P=0.03). Longer PFS (25 versus 8 weeks, P=0.02) and OS (27 versus 17 weeks, P=0.03) were also confirmed in IDA with CD109+ CECs higher than 41.1/ml but not in IDB. Patients treated with bevacizumab with or without irinotecan that were free from MRI progression after two months of treatment had significant decrease of CD109+ CECs: median PFS was 19 weeks; median OS 29 weeks. The presence of two non-contiguous lesions (distant disease) at baseline was an independent predictor of shorter PFS and OS (P<0.001). CONCLUSIONS: Data encourage further studies on the predictive potential of CD109+ CECs in GBM patients treated with bevacizumab. |
format | Online Article Text |
id | pubmed-3772091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37720912013-09-25 Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan Cuppini, Lucia Calleri, Angelica Bruzzone, Maria Grazia Prodi, Elena Anghileri, Elena Pellegatta, Serena Mancuso, Patrizia Porrati, Paola Di Stefano, Anna Luisa Ceroni, Mauro Bertolini, Francesco Finocchiaro, Gaetano Eoli, Marica PLoS One Research Article BACKGROUND: Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated in 68 patients affected by recurrent glioblastoma (rGBM) treated with bevacizumab and irinotecan and two Independent Datasets of rGBM patients respectively treated with bevacizumab alone (n=32, independent dataset A: IDA) and classical antiblastic chemotherapy (n=14, independent dataset B: IDB). METHODS: rGBM patients with KPS ≥50 were treated until progression, as defined by MRI with RANO criteria. CECs expressing CD109, a marker of tumor endothelial cells, as well as other CEC and CEP subtypes, were investigated by six-color flow cytometry. RESULTS: A baseline count of CD109+ CEC higher than 41.1/ml (1(st) quartile) was associated with increased progression free survival (PFS; 20 versus 9 weeks, P=0.008) and overall survival (OS; 32 versus 23 weeks, P=0.03). Longer PFS (25 versus 8 weeks, P=0.02) and OS (27 versus 17 weeks, P=0.03) were also confirmed in IDA with CD109+ CECs higher than 41.1/ml but not in IDB. Patients treated with bevacizumab with or without irinotecan that were free from MRI progression after two months of treatment had significant decrease of CD109+ CECs: median PFS was 19 weeks; median OS 29 weeks. The presence of two non-contiguous lesions (distant disease) at baseline was an independent predictor of shorter PFS and OS (P<0.001). CONCLUSIONS: Data encourage further studies on the predictive potential of CD109+ CECs in GBM patients treated with bevacizumab. Public Library of Science 2013-09-12 /pmc/articles/PMC3772091/ /pubmed/24069296 http://dx.doi.org/10.1371/journal.pone.0074345 Text en © 2013 Cuppini et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Cuppini, Lucia Calleri, Angelica Bruzzone, Maria Grazia Prodi, Elena Anghileri, Elena Pellegatta, Serena Mancuso, Patrizia Porrati, Paola Di Stefano, Anna Luisa Ceroni, Mauro Bertolini, Francesco Finocchiaro, Gaetano Eoli, Marica Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan |
title | Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan |
title_full | Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan |
title_fullStr | Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan |
title_full_unstemmed | Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan |
title_short | Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan |
title_sort | prognostic value of cd109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772091/ https://www.ncbi.nlm.nih.gov/pubmed/24069296 http://dx.doi.org/10.1371/journal.pone.0074345 |
work_keys_str_mv | AT cuppinilucia prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT calleriangelica prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT bruzzonemariagrazia prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT prodielena prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT anghilerielena prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT pellegattaserena prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT mancusopatrizia prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT porratipaola prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT distefanoannaluisa prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT ceronimauro prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT bertolinifrancesco prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT finocchiarogaetano prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan AT eolimarica prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan |